FDA exempts l-desoxyephedrine from final rule exemption while USP completes monograph.
This article was originally published in The Tan Sheet
Executive Summary
FDA EXEMPTS L-DESOXYEPHEDRINE FROM NASAL DECONGESTANT FINAL RULE until Dec. 31, 1996 while the U.S. Pharmacopeia completes a monograph for the ingredient. Responding to an Aug. 2 citizen petition from Leiner Health Products requesting the stay, OTC Monograph Review Staff Director William Gilbertson, PharmD, in an Aug. 31 letter, called the petition "reasonable" and said the effective date would be delayed "to permit time for USP processing."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning